- Regeneron’s COVID-19 monoclonal antibody cocktail performed well on safety and reduction of viral load
- It was not, however, tested on hospitalized patients, and limitations on pricing and the production of monoclonal antibody treatments suggest it’s no panacea for the pandemic
- Also concerning were its effects on actual symptom reduction, for which none of the groups produced a statistically significant effect
Positive results from trials are a hopeful step for a COVID-19 monoclonal antibody cocktail, but some elements of the data cast doubt on the efficacy and practicality of the treatment. The results, announced Tuesday by pharmaceutical company Regeneron, did suggest that their drug reduced viral loads and performed well on safety metrics.
“We are highly encouraged by the robust and consistent nature of these initial data, as well as the emerging well-tolerated safety profile, and we have begun discussing our findings with regulatory authorities while continuing our ongoing